Protein-based pan-RAS inhibitor induces tumor regression in female mice via IFNγ and CD8+ T cell-dependent tumor necrosis
15d ago· 1 min readNews
Source
Novel pan-RAS inhibitor, RRSP-RBD, shows promise in treating 30% of cancers with K/H/N-RAS mutations. Induces tumor regression in female mice via IFNγ & CD8+ T cells. Exciting advance! PMID:42143039, Nat Commun 2026, @NatureComms #Medsky #Pharmsky #RNA 🧪
You might also wanna read
Lab Study Finds Compound Stops 90% of Pancreatic Cancer Cell Migration
Researchers at Florida A&M University have discovered that compounds called polyisoprenylated cysteinyl amide inhibitors can stop 90% of pan

AI-guided discovery identifies GPNMB as promising CAR T cell target for multiple cancers
Researchers developed an AI-driven framework for discovering CAR T cell therapy targets by integrating single-cell RNA sequencing data from
cell.com·9d ago

Antibody-ligand motif optimization enables multitarget switchable CAR-T therapy against solid tumors
This article presents a research study on optimizing a multitarget switchable CAR-T (sCAR-T) strategy to overcome antigenic heterogeneity an
cell.com·8d ago
Programming the immunological properties of mRNA vaccines for cancer
nature.com·15d ago
Gemma-Based AI Model Identifies Potential Cancer Therapy Pathway Through Conditional Immune Amplification
Researchers used a new 27 billion parameter foundation model called C2S-Scale 27B, built on Google's Gemma family of open models, to discove
Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells
Nature Communications

Comments
Sign in to join the conversation.
No comments yet. Be the first.